Stock MNMD MIND MEDICINE (MINDMED) INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Mind Medicine (MindMed) Inc.

Equities

MNMD

CA60255C8850

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
8.68 USD -2.58% Intraday chart for Mind Medicine (MindMed) Inc. -10.24% +137.16%
Apr. 15 Leerink Partners Starts Mind Medicine (MindMed) With Outperform Rating, $20 Price Target MT
Mar. 18 Mind Medicine Inc. announced that it has received $75 million in funding from Deep Track Capital, LP, Commodore Capital CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Leerink Partners Starts Mind Medicine (MindMed) With Outperform Rating, $20 Price Target
MT
MindMed to Present at Upcoming April Medical Conferences
BU
MindMed Announces Voluntary Delisting from Cboe Canada
BU
Mind Medicine Inc. announced that it has received $75 million in funding from Deep Track Capital, LP, Commodore Capital
CI
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
BU
RBC Raises Price Target on Mind Medicine (MindMed) to $22 From $15, Keeps Outperform, Speculative Risk
MT
Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder
CI
Sector Update: Health Care Stocks Gain Late Afternoon
MT
Sector Update: Health Care Stocks Stronger in Afternoon Trading
MT
Roth MKM Raises Price Target on Mind Medicine to $36 From $25, Keeps Buy Rating
MT
Mind Medicine Gets FDA Breakthrough for Anxiety Treatment, Sees $175 Million in Proceeds From Stock Offerings; Shares Jump
MT
Mind Medicine MindMed : Investor Presentation - MM120 for Generalized Anxiety Disorder Conference Call and Webcast
PU
Transcript : Mind Medicine Inc. - Special Call
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
BU
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
BU
Mind Medicine Inc. Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data from Phase 2B Study of MM120 for Generalized Anxiety Disorder
CI
Mind Medicine Inc. announced that it expects to receive $75 million in funding from Deep Track Capital, LP, Commodore Capital
CI
Thinking about buying stock in Minim, GameSquare, Laser Photonics, Geron, or Mind Medicine?
PR
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
BU
RBC Lifts Price Target on Mind Medicine (MindMed) to $15 From $14, Notes Imminent Durability Data; Outperform, Speculative Risk Kept
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MNMD Stock
  4. News Mind Medicine (MindMed) Inc.